CN118317979A - 抗原结合多肽、抗原结合多肽复合物及其使用方法 - Google Patents

抗原结合多肽、抗原结合多肽复合物及其使用方法 Download PDF

Info

Publication number
CN118317979A
CN118317979A CN202280078695.8A CN202280078695A CN118317979A CN 118317979 A CN118317979 A CN 118317979A CN 202280078695 A CN202280078695 A CN 202280078695A CN 118317979 A CN118317979 A CN 118317979A
Authority
CN
China
Prior art keywords
polypeptide
antigen
chain variable
variable region
structure represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280078695.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·格雷奇
H·陈
L·吴
R·R·魏
L·徐
Z-Y·杨
E·孙
G·J·纳贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Modes Medical Co ltd
Original Assignee
Modes Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modes Medical Co ltd filed Critical Modes Medical Co ltd
Priority claimed from PCT/US2022/077201 external-priority patent/WO2023056313A1/en
Publication of CN118317979A publication Critical patent/CN118317979A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280078695.8A 2021-09-29 2022-09-28 抗原结合多肽、抗原结合多肽复合物及其使用方法 Pending CN118317979A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US63/249,919 2021-09-29
US63/249,722 2021-09-29
US63/249,833 2021-09-29
US63/249,794 2021-09-29
US63/291,305 2021-12-17
US202163292382P 2021-12-21 2021-12-21
US63/292,382 2021-12-21
PCT/US2022/077201 WO2023056313A1 (en) 2021-09-29 2022-09-28 Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof

Publications (1)

Publication Number Publication Date
CN118317979A true CN118317979A (zh) 2024-07-09

Family

ID=86903785

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202280078695.8A Pending CN118317979A (zh) 2021-09-29 2022-09-28 抗原结合多肽、抗原结合多肽复合物及其使用方法
CN202280078666.1A Pending CN118591388A (zh) 2021-09-29 2022-09-28 抗原结合多肽、抗原结合多肽复合物及其使用方法
CN202280072889.7A Pending CN118251411A (zh) 2021-09-29 2022-09-28 抗原结合多肽、抗原结合多肽复合物及其使用方法
CN202280089147.5A Pending CN118715247A (zh) 2021-12-21 2022-12-21 条件性活化的抗原结合多肽复合物及其使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202280078666.1A Pending CN118591388A (zh) 2021-09-29 2022-09-28 抗原结合多肽、抗原结合多肽复合物及其使用方法
CN202280072889.7A Pending CN118251411A (zh) 2021-09-29 2022-09-28 抗原结合多肽、抗原结合多肽复合物及其使用方法
CN202280089147.5A Pending CN118715247A (zh) 2021-12-21 2022-12-21 条件性活化的抗原结合多肽复合物及其使用方法

Country Status (13)

Country Link
US (1) US20240059798A1 (cg-RX-API-DMAC7.html)
EP (1) EP4452317A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025503480A (cg-RX-API-DMAC7.html)
KR (1) KR20240134257A (cg-RX-API-DMAC7.html)
CN (4) CN118317979A (cg-RX-API-DMAC7.html)
AR (1) AR128060A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022420594A1 (cg-RX-API-DMAC7.html)
CA (1) CA3240079A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001850A1 (cg-RX-API-DMAC7.html)
IL (1) IL313770A (cg-RX-API-DMAC7.html)
MX (1) MX2024007393A (cg-RX-API-DMAC7.html)
TW (1) TW202334204A (cg-RX-API-DMAC7.html)
WO (1) WO2023122659A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
WO2025249301A1 (ja) * 2024-05-27 2025-12-04 国立大学法人東京農工大学 多重特異性抗体、がん増殖抑制剤、ポリヌクレオチド及び発現ベクター
CN121248779A (zh) * 2024-06-25 2026-01-02 冕屹立生物技术(上海)有限公司 靶向人cd3分子的抗体及其应用
WO2026092759A1 (en) * 2024-11-04 2026-05-07 Modex Therapeutics, Inc. Multispecific antibodies and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US9458244B2 (en) * 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
ES2894304T3 (es) * 2015-10-25 2022-02-14 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
WO2018075564A1 (en) * 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
EA202091976A1 (ru) * 2018-02-20 2021-07-06 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на cd33, и их применение
KR20210044218A (ko) * 2018-07-11 2021-04-22 모멘타 파머슈티컬스 인코포레이티드 CD38 표적화 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
US12365722B2 (en) * 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
EP4578507A3 (en) * 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
US11613576B2 (en) * 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療hiv感染之三特異性及/或三價結合蛋白
US20230001008A1 (en) * 2019-08-20 2023-01-05 Kumquat Biosciences Inc. Compositions and methods for targeting cellular molecules
TW202330594A (zh) * 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN118613504A (zh) * 2021-12-17 2024-09-06 摩德斯医疗股份有限公司 含有tnfsf配体的细胞外结构域的抗原结合多肽复合物

Also Published As

Publication number Publication date
KR20240134257A (ko) 2024-09-06
WO2023122659A3 (en) 2023-08-03
US20240059798A1 (en) 2024-02-22
MX2024007393A (es) 2024-07-04
CN118715247A (zh) 2024-09-27
CL2024001850A1 (es) 2025-02-21
TW202334204A (zh) 2023-09-01
CN118591388A (zh) 2024-09-03
AU2022420594A1 (en) 2024-08-01
EP4452317A2 (en) 2024-10-30
AR128060A1 (es) 2024-03-20
CA3240079A1 (en) 2023-06-29
WO2023122659A2 (en) 2023-06-29
EP4452317A4 (en) 2025-12-10
JP2025503480A (ja) 2025-02-04
CN118251411A (zh) 2024-06-25
IL313770A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
US20230235092A1 (en) Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
AU2020286284B2 (en) Novel anti-CD39 antibodies
CN118251411A (zh) 抗原结合多肽、抗原结合多肽复合物及其使用方法
CN112513092B (zh) 用于治疗癌症的dll3/cd3结合蛋白
CN109476732B (zh) 三特异性和/或三价结合蛋白
CN113950484B (zh) 三特异性结合蛋白、其方法和用途
TW202128756A (zh) 用於癌症治療之多重專一性結合蛋白
CN115943161A (zh) 结合mait和肿瘤细胞两者的多特异性抗体
CN117343193A (zh) 双特异性抗体及其制备和使用方法
US20240034808A1 (en) Antigen binding polypeptide complexes containing extracellular domains of tnfsf ligands
HK40090244A (en) Multispecific antibodies that bind both mait and tumor cells
BR122024005246A2 (pt) Método de purificação de uma proteína de ligação produzida por uma célula hospedeira
IL256261A (en) Compounds and method for hide1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination